|
1
|
Lang Y, Kong X, He C, Wang F, Liu B, Zhang
S, Ning J, Zhu K and Xu S: Musashi1 promotes non-small cell lung
carcinoma malignancy and chemoresistance via activating the Akt
signaling pathway. Cell Physiol Biochem. 44:455–466. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clinic Proc. 83:584–594.
2008. View
Article : Google Scholar
|
|
3
|
Sakashita S, Sakashita M and Tsao Sound M:
Genes and pathology of non-small cell lung carcinoma. Semin Oncol.
41:28–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wakelee H, Kelly K and Edelman MJ: 50
years of progress in the systemic therapy of non-small cell lung
cancer. Am Soc Clin Oncol Educ Book. 34:177–189. 2014. View Article : Google Scholar
|
|
5
|
Du L and Morgensztern D: Chemotherapy for
advanced-stage non-small cell lung cancer. Cancer J. 21:366–370.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hasegawa T, Sawa T, Futamura Y, Horiba A,
Ishiguro T, Marui T and Yoshida T: Feasibility of rebiopsy in
non-small cell lung cancer treated with epidermal growth factor
receptor-tyrosine kinase inhibitors. Intern Med. 54:1977–1980.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franco R, Oñatibia-Astibia A and
Martínez-Pinilla E: Health benefits of methylxanthines in cacao and
chocolate. Nutrients. 5:4159–4173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boison D: Methylxanthines, seizures, and
excitotoxicity. Handb Exp Pharmacol. 251–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zubairy YF, Patil VW, Benjamin T, Jangam
D, Bijle MN and Patil S: Effect of methylxanthines (coffee/tea
consumers) on oral precancer and oral cancer patients with smoking
and smokeless tobacco habits. J Contemp Dent Pract. 13:745–758.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goel PN and Gude RP: Unravelling the
antimetastatic potential of pentoxifylline, a methylxanthine
derivative in human MDA-MB-231 breast cancer cells. Mol Cell
Biochem. 358:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lange A, Gustke H, Glassmeier G, Heine M,
Zangemeister-Wittke U, Schwarz JR, Schumacher U and Lange T:
Neuronal differentiation by indomethacin and IBMX inhibits
proliferation of small cell lung cancer cells in vitro. Lung
Cancer. 74:178–187. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malki AM, Gentry J and Evans SC:
Differential effect of selected methylxanthine derivatives on
radiosensitization of lung carcinoma cells. Exp Oncol. 28:16–24.
2006.PubMed/NCBI
|
|
13
|
Edling CE, Selvaggi F, Ghonaim R, Maffucci
T and Falasca M: Caffeine and the analog CGS 15943 inhibit cancer
cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
Cancer Biol Ther. 15:524–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lentini A, Kleinman HK, Mattioli P,
Autuori-Pezzoli V, Nicolini L, Pietrini A, Abbruzzese A, Cardinali
M and Beninati S: Inhibition of melanoma pulmonary metastasis by
methylxanthines due to decreased invasion and proliferation.
Melanoma Res. 8:131–137. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morais JA, Neves MC, Silva JR and Avila R:
Absorption of intra-bronchial diprophylline-methodology and
preliminary results. Eur J Drug Metab Pharmacokinet. 17:187–193.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basnet RM, Zizioli D, Guarienti M, Finazzi
D and Memo M: Methylxanthines induce structural and functional
alterations of the cardiac system in zebrafish embryos. BMC
Pharmacol Toxicol. 18:722017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Levi-Schaffer F and Touitou E: Xanthines
inhibit 3T3 fibroblast proliferation. Skin Pharmacol. 4:286–290.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee IA, Kamba A, Low D and Mizoguchi E:
Novel methylxanthine derivative-mediated anti-inflammatory effects
in inflammatory bowel disease. World J Gastroenterol. 20:1127–1138.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schoen K, Yu T, Stockmann C, Spigarelli MG
and Sherwin CM: Use of methylxanthine therapies for the treatment
and prevention of apnea of prematurity. Paediatr Drugs. 16:169–177.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stork PJ and Schmitt JM: Crosstalk between
cAMP and MAP kinase signaling in the regulation of cell
proliferation. Trends Cell Biol. 12:258–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ionta M, Rosa MC, Almeida RB, Freitas VM,
Rezende-Teixeira P and Machado-Santelli GM: Retinoic acid and cAMP
inhibit rat hepatocellular carcinoma cell proliferation and enhance
cell differentiation. Braz J Med Biol Res. 45:721–729. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu FF, Chen DP, Xiong YJ, Lv BC and Lin
Y: Characteristics of diprophylline-induced bidirectional
modulation on rat jejunal contractility. Korean J Physiol
Pharmacol. 18:47–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koiri RK, Mehrotra A and Trigun SK:
Targetting cancer with Ru(III/II)-phosphodiesterase inhibitor
adducts: A novel approach in the treatment of cancer. Med
Hypotheses. 80:841–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Domvri K, Zarogoulidis K, Ziogas N,
Zarogoulidis P, Petanidis S, Porpodis K, Kioseoglou E and
Hohenforst-Schmidt W: Potential synergistic effect of
phosphodiesterase inhibitors with chemotherapy in lung cancer. J
Cancer. 8:3648–3656. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scrima M, De Marco C, Fabiani F, Franco R,
Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, et
al: Signaling networks associated with AKT activation in non-small
cell lung cancer (NSCLC): New insights on the role of
phosphatydil-inositol-3 kinase. PLoS One. 7:e304272012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
